Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management - Scorecard - MDSpire

Magnetic Sphincter Augmentation and Postoperative Dysphagia: Characterization, Clinical Risk Factors, and Management

  • By

  • Shahin Ayazi

  • Ping Zheng

  • Ali H. Zaidi

  • Kristy Chovanec

  • Nobel Chowdhury

  • Madison Salvitti

  • Yoshihiro Komatsu

  • Ashten N. Omstead

  • Toshitaka Hoppo

  • Blair A. Jobe

  • August 6, 2019

  • 0 min

Share

Clinical Scorecard: Postoperative Dysphagia Following Magnetic Sphincter Augmentation: Analysis of Clinical Risk Factors and Management Strategies

At a Glance

CategoryDetail
ConditionGastroesophageal reflux disease (GERD) treated with magnetic sphincter augmentation (MSA)
Key MechanismsMagnetic sphincter augmentation enhances lower esophageal sphincter function to prevent reflux; postoperative dysphagia is a common side effect
Target PopulationAdults with symptomatic GERD refractory to maximal antisecretory therapy and objective evidence of reflux
Care SettingSpecialized surgical centers performing MSA procedures

Key Highlights

  • GERD affects approximately 25% of US adults and is commonly treated with PPIs or laparoscopic fundoplication.
  • MSA is FDA-approved since 2012 and offers comparable reflux control with fewer side effects like gas bloat compared to fundoplication.
  • Postoperative dysphagia occurs in 43–83% of MSA patients, often resolving by 8 weeks but sometimes requiring intervention.

Guideline-Based Recommendations

Diagnosis

  • Confirm GERD diagnosis with objective testing: esophageal pH or impedance-pH monitoring after PPI cessation for 10 days.
  • Perform esophagogastroduodenoscopy (EGD) with biopsy to assess esophagitis, Barrett’s esophagus, and hiatal hernia.
  • Use high-resolution impedance manometry (HRIM) to evaluate esophageal motility and sphincter pressures.

Management

  • Consider MSA for patients with persistent GERD symptoms despite maximal medical therapy and objective reflux evidence.
  • Monitor for postoperative dysphagia; most cases resolve within 8 weeks.
  • For persistent dysphagia, consider endoscopic dilation or device removal as needed.

Monitoring & Follow-up

  • Assess symptom severity and patient satisfaction pre- and postoperatively using GERD-HRQL questionnaire.
  • Follow patients closely for dysphagia symptoms post-MSA, especially within the first 8 weeks.
  • Repeat objective testing as clinically indicated to evaluate reflux control and esophageal function.

Risks

  • Postoperative dysphagia is the most common complication after MSA, occurring in up to 83% of patients early post-op.
  • Long-term PPI use carries risks including infectious diarrhea, osteoporosis, and drug interactions.
  • Laparoscopic fundoplication side effects include gas bloat, inability to belch or vomit, and anatomic failure.

Patient & Prescribing Data

Adults with symptomatic GERD refractory to medical therapy and confirmed reflux on objective testing

MSA provides effective reflux control with reduced side effects compared to fundoplication; however, clinicians should counsel patients on the high incidence of early postoperative dysphagia and its typical resolution.

Clinical Best Practices

  • Perform comprehensive preoperative evaluation including symptom assessment, GERD-HRQL scoring, EGD, HRIM, and pH monitoring.
  • Discontinue PPIs 10 days prior to pH testing to ensure accurate reflux measurement.
  • Select patients carefully excluding those with prior foregut surgery, significant esophageal dysmotility, or titanium allergy.
  • Educate patients about the likelihood of early postoperative dysphagia and the expected natural course.
  • Implement a stepwise approach to persistent dysphagia including conservative management, endoscopic dilation, and device removal if necessary.

References

Original Source(s)

Related Content